MStranslate logo
Log In
Lost your password?
Lost Password
Back to login
Search
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us
Breaking
  • Patient Community Day at MSToronto2026
  • The ECTRIMS Podcast at MSToronto2026
  • Antiviral Reverses Disability in Mouse Model of MS
  • Assessing & Monitoring Cognition in MS
  • Potential Changes to MS Treatment Access in Australia
  • MS Auckland Webinar: AHSCT as a Treatment for MS
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us

Author MStranslate

MStranslate

genetics

Genetics & MS: Can It Be Inherited?

MStranslate
June 6, 2017
Uncategorized
Recently, I’ve had the pleasure of talking to a number of different local multiple sclerosis support groups about multiple sclerosis (MS) and MS research.  These events generally involve me giving a small...
interferon-beta

Health Impacts of Interferon-beta Use in MS

MStranslate
May 16, 2017
Interferon-beta, Research, Treatments
Research Summary: Evaluating the safety of β-interferons in MS Research from the University of British Columbia has looked at the long-term health effects of interferon-beta treatment in people with...
statins

Secondary Progressive Multiple Sclerosis & Statins

MStranslate
May 15, 2017
Research, Treatments
There has been a lot of media attention recently on a trial testing statins as a treatment for multiple sclerosis (MS).  The study is being led by University College London and will involve over 1100 people...
Laquinimod

Multiple Sclerosis Clinical Trial Update: Laquinimod

MStranslate
May 9, 2017
Clinical Trials, Laquinimod, Research
What is laquinimod? Laquinimod is a once-daily oral medication that has been developed and tested for the treatment of relapsing-remitting multiple sclerosis (RRMS) and primary progressive MS (PPMS). The...
Daclizumab

Multiple Sclerosis Treatment Information: Daclizumab

MStranslate
May 3, 2017
Daclizumab, Treatments
It has been reported this week that daclizumab (marketed as Zinbryta) has been added to the Pharmaceutical Benefits Scheme (PBS) in Australia.  Considering this, we thought it appropriate to provide some more...
BMI

BMI & Lipid Levels Impact MS Progression

MStranslate
April 26, 2017
Diet, Lifestyle, Research
2 Comments
Research Summary: An adverse lipid profile and increased levels of adiposity significantly predict clinical course after a first demyelinating event An increasing emphasis is being placed on how lifestyle...

Multiple Sclerosis: One Disease, Many Causes?

MStranslate
April 18, 2017
Research, Understanding Science
1 Comment
In one of our recent Facebook Live Q&A sessions, I was asked what I thought the biggest hurdle was that needed to be overcome in multiple sclerosis research.  Whilst funding problems are something that we...

Mitochondrial Dysfunction & ER Stress in MS

MStranslate
April 4, 2017
Research, Treatments
Research Summary: Rab32 connects ER stress to mitochondrial defects in multiple sclerosis Mitochondria are often referred to as the ‘powerhouses’ of the cell, as they are largely responsible for the...
Shimmering stars

MS: Many Stories – Shimmering Stars

MStranslate
April 3, 2017
Community, MS: Many Stories
Our latest MS: Many Stories feature is written by Toni, a regular MStranslate contributor and member of our local MS community here in Melbourne, Australia.  If you haven't read Toni's previous...
Ocrevus

US FDA Approves Ocrelizumab (Ocrevus)

MStranslate
March 30, 2017
Ocrelizumab, Treatments
Ocrelizumab (Ocrevus) has been granted US FDA approval for the treatment of both replacing-remitting MS (RRMS) and primary progressive MS (PPMS).  Ocrelizumab is a monoclonal antibody that targets and...
  1. 15
  2. 16
  3. 17
  4. 18
  5. 19
  6. 20
  7. 21

Posts

  • Patient Community Day at MSToronto2026
  • The ECTRIMS Podcast at MSToronto2026
  • Antiviral Reverses Disability in Mouse Model of MS
  • Assessing & Monitoring Cognition in MS
  • Potential Changes to MS Treatment Access in Australia

Google+

Get social

Copyright 2014-2018 MStranslate. All Rights Reserved. Contact Us
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.